# Maintenance Treatment of Renal Anemia in Dialysis Subjects

Study · id `cardio:ct-nct03543657` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03543657](<https://clinicaltrials.gov/study/NCT03543657>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03543657

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 229 participants.

## Technical summary

Registry record NCT03543657. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-23 (actual); primary completion 2019-08-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 229 participants (enrolled count; ClinicalTrials.gov record NCT03543657, source copy `cardio:ctgov-nct03543657-2021-01-29`, retrieved 2026-10-26)
- Started: 2018-06-23 (actual) (ClinicalTrials.gov record NCT03543657, source copy `cardio:ctgov-nct03543657-2021-01-29`, retrieved 2026-10-26)
- Primary completion: 2019-08-07 (actual) (ClinicalTrials.gov record NCT03543657, source copy `cardio:ctgov-nct03543657-2021-01-29`, retrieved 2026-10-26)
- Completion: 2019-12-24 (actual) (ClinicalTrials.gov record NCT03543657, source copy `cardio:ctgov-nct03543657-2021-01-29`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03543657, source copy `cardio:ctgov-nct03543657-2021-01-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03543657-2021-01-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Maintenance Treatment of Renal Anemia in Dialysis Subjects
- Acronym: MIYABI HD-M
- Condition: Anemia
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): Molidustat (BAY85-3934)
- Intervention (Drug): Darbepoetin alfa
- Intervention (Drug): Placebo of Molidustat (BAY85-3934)
- Intervention (Drug): Placebo of Darbepoetin alfa
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 4645898407eebcd36d9e5b444180cc0722390255057b4e8f69cacd6ae7a1e9fc
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
